Thymosin Alpha-1

Also known as: Thymalfasin, Zadaxin, Tα1

Thymosin Alpha-1 (Tα1), a 28-amino acid peptide derived from the thymus, primarily modulates immune function by enhancing T-cell maturation, differentiation, and activation. It acts through Toll-like receptor (TLR) signaling, particularly TLR2 and TLR9, leading to increased production of cytokines such as IL-2, IFN-γ, and TNF-α. This cascade promotes dendritic cell maturation and natural killer cell activity, thereby strengthening both innate and adaptive immune responses. Its mechanism also involves upregulation of MHC class I expression and modulation of regulatory T-cell activity, contributing to its immunomodulatory profile. Key research findings demonstrate Tα1’s efficacy in improving immune responses in chronic hepatitis B and C, where it reduces viral load and enhances seroconversion rates when used alone or with interferons. Studies also show its utility as an immune adjuvant in vaccination protocols and in restoring immune function in immunocompromised patients, such as those with sepsis or post-surgical infections. Additionally, preclinical and clinical data suggest potential benefits in cancer immunotherapy by augmenting anti-tumor immune responses, though further trials are needed for definitive conclusions. Clinically, Thymosin Alpha-1 is approved in over 30 countries (e.g., as Zadaxin) for treating chronic hepatitis B and as an immune adjuvant in various infectious diseases. It is generally well-tolerated, with mild local reactions at injection sites. Ongoing research explores its role in COVID-19, HIV, and autoimmune conditions, but its use remains restricted to approved indications in specific regions. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides